DiaMedica Therapeutics Inc. - notizie pubblicate 174 - letture 1.759
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Initial Registration Statement for Employee Benefit Plan - Form S-8
Dmtp20240521_s8.htm as filed with the securities and exchange commission on may 24, 2024 registration no. 333-_______ united states securities and exchange commission washington, d ...
DIAMEDICA THERAPEUTICS INC.
Submission of Matters to a Vote of Security Holders - Form 8-K
Item 5.02 departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. at an annual general me ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
Conference call and webcast may 9 at 8:00 am eastern time / 7:00 am central time first patient dosed in relaunch of remedy2 stroke trial clinical operations team expanded to suppor ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results - Form 8-K
Diamedica therapeutics provides a business update and announces first quarter 2024 financial results conference call and webcast may 9 at 8:00 am eastern time / 7:00 am central tim ...
DIAMEDICA THERAPEUTICS INC.
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
Dmtp20240331_10q.htm united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☒quarterly report pursuant to section 13 or 15(d) of the securit ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
Minneapolis--(business wire)-- diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company currently focused on developing recombinant klk1 (dm199) for t ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
Minneapolis--(business wire)-- diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company currently focused on developing recombinant klk1 (dm199) for t ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti